Pre-clinical programs

About Cogent Biosciences

Cogent Biosciences is advancing a pipeline of precision therapies targeting genetically driven diseases, with its lead program bezuclastinib having an FDA New Drug Application accepted with a PDUFA target action date of December 30, 2026. The company operates a discovery organization in Boulder, Colorado, and is led by experienced pharmaceutical executives with expertise in oncology and hematology. Cogent's strategy focuses on improving upon existing drugs with limitations and creating breakthroughs for diseases where adequate solutions are lacking.

Therapeutic Areas